An Adaptive, Phase I, Single-Centre, Randomised, Double-blind, Placebo-controlled Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics, of Intravenous CSL112 in Healthy Volunteers.

Trial Profile

An Adaptive, Phase I, Single-Centre, Randomised, Double-blind, Placebo-controlled Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics, of Intravenous CSL112 in Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Nov 2014

At a glance

  • Drugs CSL 112 (Primary)
  • Indications Atherosclerosis; Lipid metabolism disorders
  • Focus Adverse reactions; Biomarker; Pharmacokinetics
  • Sponsors CSL
  • Most Recent Events

    • 04 Sep 2013 Results presented at the ESC Congress 2013: Annual Congress of the European Society of Cardiology.
    • 07 Nov 2012 Biomarker results presented at the 85th Annual Scientific Sessions of the American Heart Association.
    • 05 Nov 2012 Results were reported in a CSL media release, and were presented at the American Heart Associations (AHA) Scientific Sessions in November 2012.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top